BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31529048)

  • 61. Early atypical malignant transformation of diffuse low-grade astrocytoma: The importance of genotyping.
    Valente Aguiar P; Sousa O; Silva R; Vaz R; Linhares P
    Neurocirugia (Astur : Engl Ed); 2022; 33(1):31-34. PubMed ID: 34998489
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Copy Number Profiling of Brazilian Astrocytomas.
    Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
    G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
    Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Cahill DP; Choi BD; Curry WT
    Neurosurg Focus; 2024 Feb; 56(2):E2. PubMed ID: 38301244
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
    Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
    Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
    Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
    Ranade M; Epari S; Shetty O; Dhanavade S; Chavan S; Sahay A; Sahu A; Shetty P; Moiyadi A; Singh V; Dasgupta A; Chatterjee A; Kannan S; Gupta T
    J Neurooncol; 2024 Mar; 167(1):189-198. PubMed ID: 38265748
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vascular differences between IDH-wildtype glioblastoma and astrocytoma IDH-mutant grade 4 at imaging and transcriptomic levels.
    Álvarez-Torres MDM; López-Cerdán A; Andreu Z; de la Iglesia Vayá M; Fuster-Garcia E; García-García F; García-Gómez JM
    NMR Biomed; 2023 Nov; 36(11):e5004. PubMed ID: 37482922
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 69. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
    Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H
    J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772
    [TBL] [Abstract][Full Text] [Related]  

  • 70. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
    Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
    Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing.
    von Deimling A; Ono T; Shirahata M; Louis DN
    Semin Neurol; 2018 Feb; 38(1):19-23. PubMed ID: 29548048
    [TBL] [Abstract][Full Text] [Related]  

  • 72. IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
    Mandel JJ; Youssef M; Yust-Katz S; Patel AJ; Jalali A; Li Z; Wu J; Ludmir EB; de Groot JF
    J Neurol Sci; 2021 Aug; 427():117538. PubMed ID: 34146775
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
    Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
    Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
    [TBL] [Abstract][Full Text] [Related]  

  • 74. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
    Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
    Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas.
    Richardson TE; Sathe AA; Xing C; Mirchia K; Viapiano MS; Snuderl M; Abdullah KG; Hatanpaa KJ; Walker JM
    J Neuropathol Exp Neurol; 2021 Mar; 80(4):354-365. PubMed ID: 33755138
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intratumoral heterogeneity of CDKN2A deletions in IDH-mutant astrocytoma.
    Masui K; Onizuka H; Muragaki Y; Kawamata T; Kurata A; Komori T
    Brain Tumor Pathol; 2024 Apr; 41(2):92-95. PubMed ID: 38597998
    [No Abstract]   [Full Text] [Related]  

  • 77. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
    Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
    J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.
    Wijnenga MMJ; French PJ; Dubbink HJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Fleischeuer R; Dirven CMF; Vincent AJPE; van den Bent MJ
    J Neurooncol; 2018 Sep; 139(2):349-357. PubMed ID: 29663171
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A novel MRI-based deep learning networks combined with attention mechanism for predicting CDKN2A/B homozygous deletion status in IDH-mutant astrocytoma.
    Zhang L; Wang R; Gao J; Tang Y; Xu X; Kan Y; Cao X; Wen Z; Liu Z; Cui S; Li Y
    Eur Radiol; 2024 Jan; 34(1):391-399. PubMed ID: 37553486
    [TBL] [Abstract][Full Text] [Related]  

  • 80. IDH-1 polymorphisms in pilocytic astrocytomas.
    Prayson RA
    Ann Diagn Pathol; 2019 Dec; 43():151411. PubMed ID: 31677487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.